0001415889-24-015147.txt : 20240603 0001415889-24-015147.hdr.sgml : 20240603 20240603160549 ACCESSION NUMBER: 0001415889-24-015147 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240530 FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Samuel Bates CENTRAL INDEX KEY: 0001709024 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 241013603 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-06032024_080645.xml X0508 4 2024-05-30 0000744218 Celldex Therapeutics, Inc. CLDX 0001709024 Martin Samuel Bates C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP AND CFO 0 Common Stock 2024-05-30 4 M 0 25000 10.38 A 60128 D Common Stock 2024-05-30 4 S 0 35000 34.0507 D 25128 D Incentive Stock Option (Right to Buy) 10.38 2024-05-30 4 M 0 25000 0 D 2030-06-18 Common Stock 25000 80600 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin 2024-06-03